Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 12Active not recruiting 5Not yet recruiting 2Completed 2Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3CNS 2

Conditions

Urinary Bladder Neoplasms 2Muscle-invasive Urothelial Cancer of the Bladder 1Glioblastoma 1Craniopharyngioma 1Brain Neoplasms 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 251Magnetic Resonance Spectroscopy 246Cyclophosphamide 240Cisplatin 214Paclitaxel 205Radiotherapy 196Biopsy 172Gemcitabine 155Dexamethasone 150durvalumab 144atezolizumab 125Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 113Radiation 110Pemetrexed 101Etoposide 101Docetaxel 101fludarabine 97venetoclax 95Capecitabine 92Fluorouracil 91Radiosurgery 90Prednisone 89Oxaliplatin 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Transurethral Resection of Bladder × 1 year × Clear all
NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04164082 2026-05-13

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
161 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT02792582 2026-04-23

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
160 enrolled
CNS

Brain Neoplasms, Craniopharyngioma

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

Abramson Cancer Center at Penn Medicine

Phase 2 Active not recruiting
30 enrolled
CNS

Glioblastoma

NCT02621151 2025-10-07

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

NYU Langone Health

Phase 2 Active not recruiting
60 enrolled 11 charts
Genitourinary

Muscle-invasive Urothelial Cancer of the Bladder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡